Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Medchemexpress LLC MYF-03-176 | 2857937-59-6 | 99.7% | 410.37 | 1 ML
SDP

Catalog No. 5000361650
Encompass_Preferred

MYF-03-176 is an orally active inhibitor of TEAD, and suppresses TEAD transcriptional activity with an IC50 of 11 nM. The IC50 values of MYF-03-176 for TEAD1, TEAD3, and TEAD4 are 47, 32, and 71 nM, respectively. MYF-03-176 inhibits hippo signaling defective malignant pleural mesothelioma (MPM) cells. MYF-03-176 shows strong antitumor efficacy in MPM mouse xenograft model.

  • IC50 and target: IC50: TEAD1 (47 nM), TEAD2 (275 nM), TEAD3 (32 nM), TEAD4 (71 nM)
  • Cellular effect (NCI-H226): IC50 24 nM. Antiproliferative activity against human NCI-H226 cells assessed as reduction in cell viability measured for 5 days by CellTiter-Glo assay.

Catalog No. 50-003-61650 Supplier Medchemexpress LLC Supplier No. HY14713610MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

MYF-03-176 is an orally active inhibitor of TEAD, and suppresses TEAD transcriptional activity with an IC50 of 11 nM. The IC50 values of MYF-03-176 for TEAD1, TEAD3, and TEAD4 are 47, 32, and 71 nM, respectively. MYF-03-176 inhibits hippo signaling defective malignant pleural mesothelioma (MPM) cells. MYF-03-176 shows strong antitumor efficacy in MPM mouse xenograft model.

  • IC50 and target: IC50: TEAD1 (47 nM), TEAD2 (275 nM), TEAD3 (32 nM), TEAD4 (71 nM)
  • Cellular effect (NCI-H226): IC50 24 nM. Antiproliferative activity against human NCI-H226 cells assessed as reduction in cell viability measured for 5 days by CellTiter-Glo assay.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.